drugset / Trial / NCT00321477

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

NCT00321477

Phase 2 Completed 160 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.

Timeline

Start
2005-12
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule 60 mg Oral
Subject Casopitant Small molecule 120 mg Oral

Indications